Additionally, the board will consider and approve unaudited standalone & consolidated financial results for the quarter and half year ended 30 September 2025.

Further, the company’s board will also consider the declaration of 2nd interim dividend, if any, on the company’s equity shares for FY26.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

The company’s consolidated net profit jumped 24.4% to Rs 132.40 crore on 11.3% increase in net sales to Rs 669.80 crore in Q1 FY26 over Q1 FY25.